Last reviewed 2026-04-23 · How we verify

ACE-011

ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.

ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels. Used for Myelodysplastic syndromes with anemia, Chronic kidney disease-related anemia.

At a glance

Mechanism of action

ACE-011 binds to and sequesters activin ligands, preventing their interaction with activin receptors. By blocking activin signaling, which normally suppresses erythroid differentiation, the drug promotes red blood cell production. This mechanism is intended to increase hemoglobin levels in patients with anemia, particularly those with myelodysplastic syndromes or chronic kidney disease.

Approved indications

• Myelodysplastic syndromes with anemia
• Chronic kidney disease-related anemia

Common side effects

• Bone pain
• Fatigue
• Headache
• Thrombotic events

Key clinical trials

• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (PHASE3)
• Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (PHASE2)
• Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome (PHASE2)
• Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.
• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (PHASE2)
• Sotatercept in Pulmonary Arterial Hypertension (PHASE4)
• A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) (PHASE3)
• A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.